Novartis - Biotech, Pharma and Life Science Channel
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosimilars and consumer health (including over--the-counter medications).
The main pharmaceutical focus is on medications for the following areas of disease; Cardiovascular and Metabolism, Oncology (including Hematology), Neuroscience and Ophthalmics, Respiratory and Immunology and Infectious Diseases; and the portfolio contains over 50 key products. 147 products are in the pipeline.
Over 20 vaccines have been developed by Novartis, including influenza, meningitis, polio and tetanus, and the company is also developing diagnostic mechanisms for blood and protection of possible blood infections, which is used by 80% of US blood banks. Sandoz, a sub-group, has a broad portfolio helping to make affordable, high-quality medicines available to patients around the world and stabilize healthcare systems.
Source; BioPortfolio.com and Novartis.com
Add the Novartis News Channel to your RSS reader;
Follow the Novartis Twitter feed;
News Articles
Novartis International AG / Key vildagliptin data in The Lancet show for the first time individualized HbA1c treatment goals can be reached in elderly type 2 diabetes patients with no major tolerabi...
Novartis International AG / New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations . Processed and tran...
BURLINGTON, Mass., May 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an em...
Novartis International AG / Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement . Processed and transmitte...
Novartis wins GBCHealth Business Action on Health Award for social ventures initiative
Novartis International AG / Novartis wins GBCHealth Business Action on Health Award for social ventures initiative . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsibl...
Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic Partners
Atlas Venture is pleased to announce that it has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, a...
NextPharma Technologies Holding Limited, one of the leading contract manufacturers in Europe for the pharmaceutical, biotechnology and healthcare industries, is delighted to annou...
Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
LA JOLLA, Calif. and ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- A team of international researchers from the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc. (SGI), Novartis Vaccines a...
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Financing Reflects Encouraging Clinical Progress with Galeterone in Prostate Cancer Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developin...
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZe...
Events
None
Companies
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for th...
Neovacs is a French biotechnology company focused on active immunotherapy for autoimmune and inflammatory diseases and cancer. Neovacs is a spin-off from Université Pierre et Marie Curie in P...
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery...
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The companyâs lead drug candidate, TOK-001, is the first i...
Novartis's name, derived from the Latin novae artes, means "new skills" and reflects Novartis's commitment to focus research and development to bring new healthcare products to the...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...
BioRelix, Inc, is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products b...
Ansaris is a division of Locus Pharmaceuticals, a privately held biopharmaceutical company focused on solving todayâs small molecule drug discovery challenges, has been the l...
Hill Hollidayâs purpose is to create a singular, resonant idea upon which a company can build business success that endures for years, even decades. The ultimate reward for s...
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew Universityâs intellectual property....
Clinical Trials
Role of Glivec in Patients With Tumor Cells Positive for c-Kit or PDGFR; a Multi Center Study.
This is a phase II, multi-center (Israeli), open label, non-randomized trial for every patient with the specified tumors expressing c-kit or PDGFR. Expression of these kinases will be inv...
This phase III is designed to confirm the previous trial results evaluating the safety, clinical tolerability and immunogenicity of the 2006-2007 formulation of Novartis Vaccines' adjuvant...
This study will evaluate the bioequivalence as well as rate and extent of absorption of vildagliptin tablet manufactured by Beijing Novartis Pharma Ltd. compared to the imported vildaglipt...
The purpose of this study is to evaluate the efficiency of a rapid diagnostic test (Paracheck Pf) for the diagnosis of uncomplicated Plasmodium falciparum malaria by community health worke...
The purpose of this study is to assess the clinical anti-proliferative activity of STI571 (Glivec®, Novartis, Pharma) in patients with HES defined as: 1. Idiopathic Hypereosinophilic S...
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
Medications available for the treatment of seasonal allergic conjunctivitis include antihistamines. These medicines block the release of histamine, a substance in the body that is released...
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with...
There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients are at an...
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
High-dose interleukin 2 (Proleukin, Novartis) (IL-2) is approved by the U.S Food and Drug Administration (FDA) for the treatment of metastatic kidney cancer and is a standard treatment of...
This phase II, open label, is designed as a seasonal study to support annual strain update evaluating the safety, clinical tolerability and immunogenicity of the 2007-2008 formulation of...
PubMed Articles
This retrospective analysis of hip fracture patients with and without muscle atrophy/weakness (MAW) revealed that those with MAW had significantly higher healthcare utilization and costs compared with...
A victory for global public health in the Indian Supreme Court.
On 1 April of this year, the Indian Supreme Court upheld the decision of the Indian Patent Office to refuse the patent grant for Novartis imatinib mesylate (Gleevec). The patent application failed to...
Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD.
We present a clinical proof-of-concept (PoC) study in chronic obstructive pulmonary disease with the objective of assessing the bronchodilatory effect of an experimental drug as compared with an activ...
Memory and other properties of multiple test procedures generated by entangled graphs.
Methods for addressing multiplicity in clinical trials have attracted much attention during the past 20 years. They include the investigation of new classes of multiple test procedures, such as fixe...
Induction immunosuppression in liver transplantation: a review.
Antibody therapy for induction is seldom used in liver transplantation in the United States, but continues to be used in approximately 10% of patients. The most commonly used antibody at the current t...
Systems formed using the V(IV)O(2+) ion with tridentate ligands containing a (O, Narom, O) donor set were described. Examined ligands were 3,5-bis(2-hydroxyphenyl)-1-phenyl-1H-1,2,4-triazole (H2hyph(P...
Invasive nontyphoidal Salmonella disease in Africa: current status.
Runx2 is a master regulator of bone development and has also been described as an oncogene. Estrogen Receptor α (ERα) and Estrogen Related Receptor α (ERRα), both implicated in bone metabolism and...
BACKGROUND: Several comparison studies showed that the Ultrio assay (Novartis Diagnostics) used in individual-donation nucleic acid amplification testing (ID-NAT) format was as sensitive as the TaqScr...
Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?
BACKGROUND: Hepatitis B virus (HBV) DNA-positive yield since nucleic acid testing (NAT) implementation (minipools of 16 [MP16]) was reported for the first year. We have updated those figures, evalua...
Videos
BUSINESS BULLETIN - India denies Novartis patent protection on cancer drug
Novartis loses out on its patent application for cancer drug Glivac in India. It says that will "discourage innovation". It's an important case in a country ...
